Aggregate investment in 64 biopharmaceutical investments.
This document is a confidential financial report summarizing the investment performance of New Leaf Ventures and Sprout Funds by sector as of March 31, 2014. It details performance metrics (Gross Value, Multiple, and IRR) for Biopharmaceutical and Information Convergence investments across multiple funds dating back to 1993. The document carries a House Oversight Committee stamp, indicating it was part of a congressional investigation.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein financial record